1-6 of 6
Julie R. Nangia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer

Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, Robert Davis, Tao Wang, Tomas Pascual, Pier Selenica, Katherine Sanchez, Hiroaki Nitta, Monesh Kapadia, Anne C. Pavlick, Patricia Galvan, Brent Rexer, Andres Forero-Torres, Rita Nanda, Anna M. Storniolo, Ian E. Krop, Matthew P. Goetz, Julie R. Nangia, Antonio C. Wolff, Britta Weigelt, Jorge S. Reis-Filho, Susan G. Hilsenbeck, Aleix Prat, C. Kent Osborne, Rachel Schiff, Mothaffar F. Rimawi
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3101–3109.
https://doi.org/10.1158/1078-0432.CCR-22-3753
Published: 15 August 2023
View articletitled, A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer
Open the PDF for A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer in another window
Includes: Supplementary data
Journal Articles

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

Cynthia X. Ma, Jingqin Luo, Rachel A. Freedman, Timothy J. Pluard, Julie R. Nangia, Janice Lu, Frances Valdez-Albini, Melody Cobleigh, Jason M. Jones, Nancy U. Lin, Eric P. Winer, P. Kelly Marcom, Shana Thomas, Jill Anderson, Brittney Haas, Leslie Bucheit, Richard Bryce, Alshad S. Lalani, Lisa A. Carey, Matthew P. Goetz, Feng Gao, Gretchen Kimmick, Mark D. Pegram, Matthew J. Ellis, Ron Bose
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1258–1267.
https://doi.org/10.1158/1078-0432.CCR-21-3418
Published: 01 April 2022
View articletitled, The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Open the PDF for The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer

Brian D. Lehmann, Vandana G. Abramson, Melinda E. Sanders, Erica L. Mayer, Tufia C. Haddad, Rita Nanda, Catherine Van Poznak, Anna Maria Storniolo, Julie R. Nangia, Paula I. Gonzalez-Ericsson, Violeta Sanchez, Kimberly N. Johnson, Richard G. Abramson, Sheau-Chiann Chen, Yu Shyr, Carlos L. Arteaga, Antonio C. Wolff, Jennifer A. Pietenpol
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2111–2123.
https://doi.org/10.1158/1078-0432.CCR-19-2170
Published: 01 May 2020
View articletitled, TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer
Open the PDF for TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer

Mothaffar F. Rimawi, Polly Niravath, Tao Wang, Brent N. Rexer, Andres Forero, Antonio C. Wolff, Rita Nanda, Anna M. Storniolo, Ian Krop, Matthew P. Goetz, Julie R. Nangia, Sao Jiralerspong, Anne Pavlick, Jamunarani Veeraraghavan, Carmine De Angelis, Carolina Gutierrez, Rachel Schiff, Susan G. Hilsenbeck, C. Kent Osborne
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (4): 821–827.
https://doi.org/10.1158/1078-0432.CCR-19-0851
Published: 14 February 2020
View articletitled, TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Open the PDF for TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019

Costanza Paoletti, Yufeng Li, Maria C. Muñiz, Kelley M. Kidwell, Kimberly Aung, Dafydd G. Thomas, Martha E. Brown, Vandana G. Abramson, William J. Irvin, Jr, Nancy U. Lin, Minetta C. Liu, Rita Nanda, Julie R. Nangia, Anna M. Storniolo, Tiffany A. Traina, Christos Vaklavas, Catherine H. Van Poznak, Antonio C. Wolff, Andres Forero-Torres, Daniel F. Hayes
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2771–2779.
https://doi.org/10.1158/1078-0432.CCR-14-2781
Published: 14 June 2015
View articletitled, Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
Open the PDF for Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019 in another window
Includes: Supplementary data
Journal Articles

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer

Andres Forero-Torres, Katherine E. Varley, Vandana G. Abramson, Yufeng Li, Christos Vaklavas, Nancy U. Lin, Minetta C. Liu, Hope S. Rugo, Rita Nanda, Anna M. Storniolo, Tiffany A. Traina, Sujata Patil, Catherine H. Van Poznak, Julie R. Nangia, William J. Irvin, Jr, Helen Krontiras, Jennifer F. De Los Santos, Paul Haluska, William Grizzle, Richard M. Myers, Antonio C. Wolff
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2722–2729.
https://doi.org/10.1158/1078-0432.CCR-14-2780
Published: 14 June 2015
View articletitled, TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
Open the PDF for TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer in another window
Includes: Supplementary data